



(51) International Patent Classification:

C07D 307/84 (2006.01) **C07D 413/12** (2006.01)
C07D 405/04 (2006.01) **C07D 417/10** (2006.01)
C07D 405/10 (2006.01) **C07D 417/12** (2006.01)
C07D 405/12 (2006.01) **C07D 453/00** (2006.01)
C07D 407/12 (2006.01) **C07D 491/10** (2006.01)
C07D 409/12 (2006.01) **A61K 31/14** (2006.01)
C07D 413/10 (2006.01) **A61P 31/14** (2006.01)

(21) International Application Number:

PCT/US2009/056166

(22) International Filing Date:

8 September 2009 (08.09.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/096,005 11 September 2008 (11.09.2008) US

(71) **Applicant** (for all designated States except US): **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543-4000 (US).

(72) Inventors; and

(75) **Inventors/Applicants** (for US only): **YEUNG, Kap-Sun** [US/US]; c/o Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **PARCELLA, Kyle E.** [US/US]; c/o Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **BENDER, John A.** [US/US]; c/o Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **BENO, Brett R.** [US/US]; c/o Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **GRANT-YOUNG, Katharine A.** [US/US]; c/o Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **HAN, Ying** [US/US]; c/o Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **HEWAWASAM, Piyasena** [US/US]; c/o Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US).

KADOW, John F. [US/US]; c/o Bristol Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **NICKEL, Andrew** [US/US]; 572 S. Berkeley Avenue, San Marino, California 91108 (US).

(74) **Agents:** **EPPERSON, James** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) **Title:** COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

(57) **Abstract:** The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

